Sonoko Misawa

Sonoko Misawa

Auto-generated profile, based on publicly available information

Sonoko Misawa

Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2018 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
KWKeisuke Watanabe
Keisuke Watanabe
SHShigeki Hirano
Shigeki Hirano
KKKazuho Kojima
Kazuho Kojima
KNKengo Nagashima
Kengo Nagashima
HMHiroki Mukai
Hiroki Mukai
SMSonoko Misawa
Sonoko Misawa
Objective To assess the cerebral blood flow (CBF) in patients with diabetic neuropathic pain, and its changes after duloxetine therapy. Methods Using iodine-123-N-isopropyl-p-iodoamphetamine single-photon emission computed tomography (IMP-SPECT), we performed a cross-sectional study of 44 patients with diabetes, and compared CBF in those with (n = 24) and without neuropathic pain (n = 20). In patients with neuropathic pain, we also longitudinally assessed changes in CBF 3 months after treatment with duloxetine. Results IMP-SPECT with voxel-based analyses showed a significant increase in cerebral blood flow in the right anterior cingulate cortex and a decrease in the left ventral striatum in patients with neuropathic pain, compared with those without pain. After duloxetine treatment, volume of interest analyses revealed a decrease in cerebral blood flow in the anterior cingulate cortex in patients with significant pain relief but not in non-responders. Furthermore, voxel-based whole brain correlation analyses demonstrated that greater baseline CBF in the anterior cingulate cortex was associated with better pain relief on the numerical rating scale. Conclusions Our results suggest that the development of neuropathic pain is associated with increased activity in the anterior cingulate cortex, and greater baseline activation of this region may predict treatment responsiveness to pharmacological intervention. Trial registration number UMIN000017130;Results.

1 February 2007 in Clinical Neurophysiology
Verified
Journal Article
Closed access
SKSatoshi Kuwabara
Satoshi Kuwabara
SMSonoko Misawa
Sonoko Misawa
KKKazuaki Kanai
Kazuaki Kanai
NTNoriko Tamura
Noriko Tamura
MNMiho Nakata
Miho Nakata
THTakamichi Hattori
Takamichi Hattori

26 March 2024 in Neurology
Verified
Journal Article
Closed access
YAYuya Aotsuka
Yuya Aotsuka
SMSonoko Misawa
Sonoko Misawa
TSTomoki Suichi
Tomoki Suichi
KSKazumoto Shibuya
Kazumoto Shibuya
KNKeigo Nakamura
Keigo Nakamura
SKSatoshi Kuwabara
Satoshi Kuwabara
To investigate the current epidemiology, clinical profile, and treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) using a nationwide survey in Japan. We conducted a nationwide survey using an epidemiologic method established in 2021. Questionnaire sheets were sent to the hospital departments of neurology and pediatric neurology throughout Japan. A primary questionnaire was used to determine the number of patients and their prevalence, and a second questionnaire was used to collect detailed clinical information. The primary survey showed that the estimated number of patients with CIDP was 4,180, with a prevalence of 3.3 per 100,000 persons. In the secondary survey, detailed clinical data were available for 1,257 patients. The male-to-female ratio was 1.5:1, and the median age at onset was 52 years. Typical CIDP was the most frequent subtype (52%), followed by distal (17%) and multifocal/focal CIDP (17%). Initial treatments included immunoglobulin therapy (72%), corticosteroids (15%), and others (13%). Among patients with CIDP, 78% had a progressive/relapsing course, 14% did not respond to first-line treatments, and 18% could not walk independently at the last visit. Among the subtypes, typical CIDP had the most severe disability before treatment (44% of patients could not walk independently). However, they showed a more favorable response to treatment than those with distal or multifocal CIDP. In the subgroup analyses, logistic regression analyses showed that younger age at onset, no muscle atrophy, and abnormal median-normal sural sensory nerve responses were associated with a higher probability of independent walking. Our study represents the largest cohort study on CIDP to demonstrate the current epidemiologic and clinical status of CIDP in Japan. Clinical subtypes seem to be associated with different treatment responses and outcomes; therefore, an appropriate treatment strategy according to the pathophysiology of each subtype is required to improve the prognosis of CIDP.

20 November 2020 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
SKSatoshi Kuwabara
Satoshi Kuwabara
TSTomoki Suichi
Tomoki Suichi
SMSonoko Misawa
Sonoko Misawa
Separately, chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated demyelinating neuropathy; the reported prevalence ranges from 0.8 to 8.9 per 100 000 people.3 The diagnosis of CIDP is based on electrodiagnostic evidence of peripheral nerve demyelination, and exclusion criteria. Both patients with POEMS and CIDP show symmetric demyelinating polyneuropathy, and previous studies have shown that up to 60% of patients with POEMS syndrome were initially diagnosed as having CIDP by neurologists; specifically, actually 70% of patients with POEMS fulfilled the electrodiagnostic criteria for definite CIDP.4 The fact is very critical in clinical practice; many patients with POEMS syndrome are misdiagnosed with CIDP, and …

1 November 2017 in The American Journal of Medicine
Verified
Journal Article
Open access
SSShingo Suzuki
Shingo Suzuki
SMSonoko Misawa
Sonoko Misawa
TOTakahiro Ota
Takahiro Ota
YLYu Li
Yu Li
SKSatoshi Kuwabara
Satoshi Kuwabara
MIMasatomi Ikusaka
Masatomi Ikusaka

29 March 2019 in Amyloid
Verified
Journal Article
Closed access
TYTaro Yamashita
Taro Yamashita
MUMitsuharu Ueda
Mitsuharu Ueda
SMSonoko Misawa
Sonoko Misawa
YIYasuteru Inoue
Yasuteru Inoue
TMTeruaki Masuda
Teruaki Masuda
YAYusuke Ando
Yusuke Ando
(2019). Changes in nerve excitability indices in hereditary transthyretin amyloidosis. Amyloid: Vol. 26, Proceedings of the XVI International Symposium on Amyloidosis Kumamoto, Japan 26-29 March 2018, pp. 9-10.